(Reuters) - Israel-based VBL Therapeutics said a mid-stage study of its experimental brain cancer drug met the main goal of increasing overall survival. The company said a combination of its drug, VBL-111, and Roche AG's cancer treatment, Avastin, significantly improved overall survival, compared with patients only given Avastin. The company said it discontinued testing the drug as a monotherapy after nearly half the patients in the study saw the disease progress when given only VBL-111. (Reporting by Vidya L Nathan in Bengaluru; Editing by Maju Samuel) via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment